Literature DB >> 32023587

Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.

Anna So1, Kazuhiko Sakaguchi1,2, Yuko Okada1, Yasuko Morita1, Tomoko Yamada1, Hiroshi Miura1, Natsu Otowa-Suematsu1, Tomoaki Nakamura1,3, Hisako Komada1, Yushi Hirota1, Yoshikazu Tamori1,4, Wataru Ogawa1.   

Abstract

We had aimed to determine whether homeostasis model assessment-insulin resistance (HOMA-IR) reflects insulin resistance-sensitivity during treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2i). Hyperinsulinemic-euglycemic clamp analysis was performed in 22 patients with type 2 diabetic patients taking dapagliflozin (5 mg/day before or after breakfast). Propensity score matching of these individuals (SGLT2i group) for age, sex, body mass index, and clamp-derived tissue glucose uptake rate with 44 type 2 diabetic patients who had undergone clamp analysis without SGLT2i treatment (control group) identified 17 paired subjects in each group for further analysis of the relation between HOMA-IR and a clamp-derived insulin sensitivity index (ISI). Natural log-transformed HOMA-IR was negatively correlated with ISI in both SGLT2i (r = -0.527, p = 0.030) and control (r = -0.534, p = 0.027) groups. The simple regression lines for log-transformed HOMA-IR and ISI in the two groups showed similar slopes but differed in their intercepts. Multivariate analysis revealed that HOMA-IR for patients with the same ISI in the two groups was related by the formula: HOMA-IRcontrol = HOMA-IRSGLT2i × 2.45. In conclusion, HOMA-IR was well correlated with ISI during SGLT2i treatment, but values corresponding to the same ISI were lower in the SGLT2i group than in the control group.

Entities:  

Keywords:  Homeostasis model assessment–insulin resistance (HOMA-IR); Hyperinsulinemic-euglycemic clamp; Insulin resistance; Insulin sensitivity; Sodium-glucose cotransporter 2 (SGLT2) inhibitor

Mesh:

Substances:

Year:  2020        PMID: 32023587     DOI: 10.1507/endocrj.EJ19-0445

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Effect of high-fat diet for rats at different stages on glucose and lipid metabolism in offspring and related mechanisms.

Authors:  Ming Wei; Di Zhan; Zhu-Xi Li; Huan-Yu Wang; Ying Xing; Xiao-Ping Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-11-15

2.  Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial.

Authors:  Tao Yuan; Shixuan Liu; Yingyue Dong; Yong Fu; Yan Tang; Weigang Zhao
Journal:  Diabetol Metab Syndr       Date:  2020-10-27       Impact factor: 3.320

3.  Association between physical activity and insulin resistance using the homeostatic model assessment for insulin resistance independent of waist circumference.

Authors:  Tae Kyung Yoo; Byeong Kil Oh; Mi Yeon Lee; Ki-Chul Sung
Journal:  Sci Rep       Date:  2022-04-09       Impact factor: 4.379

Review 4.  Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism.

Authors:  Decio Armanini; Marco Boscaro; Luciana Bordin; Chiara Sabbadin
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

5.  Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.

Authors:  Atsushi Tanaka; Takumi Imai; Michio Shimabukuro; Isao Taguchi; Akira Sezai; Shigeru Toyoda; Hirotaka Watada; Junya Ako; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2022-08-08       Impact factor: 8.949

Review 6.  Insulin Resistance and Type 2 Diabetes Mellitus: An Ultimatum to Renal Physiology.

Authors:  Susmita Sinha; Mainul Haque
Journal:  Cureus       Date:  2022-09-08

7.  Newly proposed insulin resistance indexes called TyG-NC and TyG-NHtR show efficacy in diagnosing the metabolic syndrome.

Authors:  M Mirr; D Skrypnik; P Bogdański; M Owecki
Journal:  J Endocrinol Invest       Date:  2021-06-16       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.